Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
55%
Relapsed or Refractory multiple Myeloma
42%
Acute Myeloid Leukemia
28%
Lenalidomide
23%
Carfilzomib
22%
Overall Survival
20%
Myelodysplastic Syndrome
18%
Bortezomib
17%
Graft-versus-host Disease (GvHD)
17%
Phase II Study
17%
Myeloma
16%
Protease Inhibitors
15%
Granulocyte Colony-stimulating Factor (G-CSF)
14%
Unrelated Donor
12%
Confidence Interval
12%
Multiple Myeloma Patients
12%
Progression-free Survival
11%
Overall Response Rate
11%
Leukemia
10%
Autologous Transplantation
10%
Myeloma Cells
10%
Reduced-intensity Conditioning
10%
Transplantation
9%
Chronic Myeloid Leukemia
8%
Hematopoietic Cell Transplantation
7%
Allogeneic Transplantation
7%
Complete Remission
7%
Hazard Ratio
7%
Marrow Transplantation
7%
Non-Hodgkin Lymphoma
7%
Chemotherapy
7%
Relapsed or Refractory
7%
Peripheral Blood
7%
Allogeneic Peripheral Blood Stem Cell Transplantation
7%
Older Patients
7%
Azacitidine
7%
Total Body Irradiation
7%
Phase II Trial
6%
Adverse Events
6%
High Risk
6%
Pomalidomide
6%
Leukemia Patients
6%
Pretransplant
6%
Bone Marrow
6%
Older Adults
6%
Cyclophosphamide
6%
Maintenance Therapy
6%
Cytarabine
6%
Daratumumab
5%
Medicine and Dentistry
Multiple Myeloma
92%
Hematopoietic Cell
24%
Overall Survival
22%
Acute Myeloid Leukemia
22%
Transplantation
20%
Cell Transplantation
19%
Carfilzomib
19%
Myeloma
15%
Lenalidomide
15%
Diseases
14%
Myelodysplastic Syndrome
14%
Bortezomib
12%
Malignant Neoplasm
11%
Proteasome Inhibitor
11%
Progression Free Survival
10%
Allograft
9%
Stem Cell Transplant
9%
Dexamethasone
9%
Adverse Event
9%
Autologous Stem Cell Transplantation
9%
Leukemia
9%
Granulocyte Colony Stimulating Factor
8%
Reduced Intensity Conditioning
8%
Hazard Ratio
8%
Arm
7%
Graft Versus Host Reaction
7%
Chronic Myelogenous Leukemia
7%
Autotransplantation
7%
Low Drug Dose
6%
Drug Resistance
6%
Azacitidine
6%
Myeloma Cell
5%
Conditioning
5%
Acute Lymphoblastic Leukemia
5%
Neoplasm
5%
Whole Body Radiation
5%
Cyclophosphamide
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
81%
Lenalidomide
21%
Acute Myeloid Leukemia
20%
Dexamethasone
17%
Myelodysplastic Syndrome
16%
Overall Survival
15%
Diseases
15%
Bortezomib
14%
Myeloma
13%
Malignant Neoplasm
11%
Remission
11%
Adverse Event
10%
Carfilzomib
9%
Progression Free Survival
9%
Proteasome Inhibitor
8%
Cyclophosphamide
7%
Azacitidine
7%
Pharmacokinetics
6%
Chemotherapy
6%
Granulocyte Colony Stimulating Factor
6%
Graft Versus Host Reaction
6%
Drug Resistance
6%
Cytarabine
5%
Leukemia
5%
Elotuzumab
5%
Plerixafor
5%